Kalinsky, K. http://orcid.org/0000-0002-1583-3553
Sparano, J. A.
Zhong, X.
Andreopoulou, E.
Taback, B.
Wiechmann, L.
Feldman, S. M.
Ananthakrishnan, P.
Ahmad, A.
Cremers, S.
Sireci, A. N.
Cross, J. R.
Marks, D. K.
Mundi, P.
Connolly, E.
Crew, K. D.
Maurer, M. A.
Hibshoosh, H.
Lee, S.
Hershman, D. L.
Funding for this research was provided by:
Women at Risk
National Cancer Institute (N01-CM-62204)
National Institutes of Health (TR000081)
Article History
Received: 13 February 2018
Accepted: 26 April 2018
First Online: 7 May 2018
Compliance with ethical standards
:
: The authors would like to report the following conflicts of interest: KK (Advisory: Biotheranostics, Lilly, Pfizer, Amgen, Novartis, Eisai) and MM (Stock and Employment: Bristol-Myers Squibb).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.